AUTHORIZED WHOLESALE DISTRIBUTORS

FOR TREMFYA™ (guselkumab)

TREMFYA™ is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is administered by subcutaneous injection. The recommended dose is 100 mg at Week 0, Week 4, and every 8 weeks thereafter.

10-digit NDC number: 57894-640-01

11-digit NDC number: 57894-0640-01

Package contents: TREMFYA™ Injection is supplied as a single-dose 100 mg/mL prefilled syringe. TREMFYA™ is a clear and colorless to light yellow solution that may contain small translucent particles.

Distributors List*	
AMERISOURCEBERGEN DRUG COMPANY	H.D. SMITH WHOLESALE DRUG CO.
ANDA PHARMACEUTICAL INC	HARVARD DRUG GROUP, LLC
BELLCO HEALTH	J.M. BLANCO (SUBSIDIARY OF AMERISOURCEBERGEN DRUG COMPANY)
BURLINGTON DRUG COMPANY	KINRAY, INC
CAPITAL WHOLESALE DRUG CO.	McKESSON CORPORATION
CARDINAL HEALTH P.R. 120, INC.	MIAMI-LUKEN, INC.
CARDINAL HEALTH, INC.	MORRIS & DICKSON COMPANY, LTD.
CESAR CASTILLO, INC.	NC MUTUAL WHOLESALE DRUG COMPANY
DAKOTA DRUG, INC.	PHARMACY BUYING ASSOCIATION, INC.
DIK DRUG COMPANY	PRESCRIPTION SUPPLY INC.
DMS PHARMACEUTICAL GROUP, INC.	R&S NORTHEAST DRUG CO, INC
DROGUERIA BETANCES, INC.	ROCHESTER DRUG COOP, INC.
DROGUERIA CENTRAL, INC.	SMITH DRUG COMPANY
FRANK W. KERR COMPANY	VALLEY WHOLESALE DRUG CO.
GENERAL INJECTABLES & VACCINES (HENRY SCHEIN, INC.)	VALUE DRUG COMPANY, INC.

*List is accurate as of day of printing, please refer to www.JOM.com for latest information.

Selected Important Safety Information

TREMFYA™ may increase the risk of infection. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a clinically important or serious infection develops, discontinue TREMFYA™ until infection resolves. Evaluate for tuberculosis before treating with TREMFYA™. Avoid use of live vaccines in patients treated with TREMFYA™. Please see related and other Important Safety Information on the following page.

Tremfya™ (guselkumab)

janssen Immunology

PHARMACEUTICAL COMPANIES OF Johnson & Johnson

Important Safety Information

Infections

TREMFYA™ may increase the risk of infection. Treatment with TREMFYA™ should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA™ in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA™ to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA™ until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)

Evaluate patients for TB infection prior to initiating treatment with TREMFYA™. Initiate treatment of latent TB prior to administering TREMFYA™. Monitor patients for signs and symptoms of active TB during and after TREMFYA™ treatment. Do not administer TREMFYA™ to patients with active TB infection.

Immunizations

Prior to initiating TREMFYA™, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA™.

Adverse Reactions

Most common (≥1%) adverse reactions associated with TREMFYA™ include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

Please read the full Prescribing Information and Medication Guide for TREMFYA™. Provide the Medication Guide to your patients and encourage discussion.

067010-170208

Tremfya™ (guselkumab)

janssen Immunology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson